Gossamer Bio, Inc.
GOSS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001728117
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
173
- −20 vs. Q1 2026
- Total value $74.96M
Superinvestors holding GOSS
1
- At the end of Q2 2026
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by GOSS insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2025 | Aug 19, 2025 | Milligan SandraDirector | PPurchaseCommon Stock | +26.05K | $1.92 | +$50.02K | 58.05K | +81.4% | SEC |
| Jun 25, 2024 | Jun 24, 2024 | Aranda RichardChief Medical Officer | SSaleCommon Stock | −1.91K | $0.66 | −$1.26K | 196.89K | −1.0% | SEC |
| Jun 24, 2024 | Jun 21, 2024 | Hasnain FaheemPresident & CEO | PPurchaseCommon Stock | +372K | $0.67 | +$249.24K | 5.41M | +7.4% | SEC |
| Jun 20, 2024 | Jun 18, 2024 | Giraudo BryanCOO/CFO | PPurchaseCommon Stock | +100K | $0.59 | +$59K | 480.01K | +26.3% | SEC |
| Jun 20, 2024 | Jun 17, 2024 | Smith Robert Paul JRChief Commercial Officer | PPurchaseCommon Stock | +25K | $0.60 | +$15K | 25K | New position | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in GOSS at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | – | $11.47M | 0.52% | – | New |
| D. E. Shaw & Co., Inc. | 40,959,285 | $6.74M | 0.00% | +40,569,854+10,417.7% | Added |
| 683 Capital Management, LLC | 39,198,868 | $6.45M | 0.59% | +34,198,868+684.0% | Added |
| DeepCurrents Investment Group LLC | 37,665,073 | $6.03M | 0.21% | – | – |
| Context Capital Management, LLC | 28,946,459 | $4.76M | 0.10% | – | – |